 So I'd just like to firstly thank the Brain Foundation for this generous gift also the scientific committee and all the committee itself and also my family and my partner Greta who's here So the focus of my research is really to develop a liquid biopsy for neuro degeneration So what is a liquid biopsy? Really? It's the analysis of cell-free DNA. And so Cell-free DNA a little bits of DNA that float around within our blood in our blood and they come in a variety of different forms in Mothers expecting you can find cell-free DNA from the fetus itself in cancer patients you can find cell-free DNA of the cancer and so Using the analysis of these fragments. We can diagnose genetic disorders At before birth and we can track cancer patients and diagnose cancer patients so really I wanted to generate a method for Analyzing cell-free DNA in neurology And this has a great potential because you don't need to directly biopsy these hard to reach tissues such as the brain So with the generous gift of the Brain Foundation We've begun working on developing a technology that can identify brain-derived cell-free DNA and We will apply this to initially to frontal temporal dementia patients excuse me the This the frontal temporary dementia comes in a number of subtypes With broadly speaking, it's a behavior. There's a behavioral subtype that's associated with behavioral changes And then there's a primary progressive aphasia. It's associated with language disturbances and it's not so surprising that the Degeneration in the brain occurs in regions that are Responsible for the function of behavior and and speech in these in these patients and so What we're going to do is is What this what this funding allows us to do is generate new markers for these regions that are lost in these patients and Through this we'll be able to profile the bloods of patients and Subtype frontal temporal dementia through the blood We'll also be able to hopefully diagnose Frontal temporal dementia from the blood now this has a broad application to neurodegenerative diseases generally But Basically, it creates a it will hopefully create a blood-based test test that's cheap and and can be applied on a population level so that a clinician in a general follow-up can apply this to a potential Patient or in a pre-symptomatic stage and and potentially a Identify patients that haven't even Progress with clinical symptoms yet. So again, I'd like to thank the Brain Foundation for all their generous Thank you